Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CYTOTOXICTISALANS

Financiado

Cerrado

Salan Ti IV Complexes as Novel Anti Cancer Chemotherapeutics

"Cisplatin is a platinum-based complex used widely as a chemotherapeutic drug. However, due to its limitations, including narrow activity range and severe side effects, other transition metal complexes are investigated as antitumo... ver más

31/05/2013

THE HEBREW UNIVERS...

168K€

Presupuesto del proyecto: 168K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-05-31 No tenemos la información de la convocatoria

0% 89% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

THE HEBREW UNIVERSITY OF JER...

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

safenolaTiCancerDrug Highly and Widely Effective Water Stable and Non Toxic Tit... 150K€ Cerrado

DINURU The Synthesis and Evaluation of Organometallic Dinuclear Rut... 179K€ Cerrado

Organomet Novel organometallic anticancer compounds 157K€ Cerrado

CTQ2008-02064 ACTIVIDAD ANTITUMORAL E INHIBIDORA DE TELOMERASAS DE COMPUES... 83K€ Cerrado

CTQ2015-64319-R METALOFARMACOS PARA EL TRATAMIENTO DEL CANCER Y ESTRATEGIAS... 121K€ Cerrado

PID2021-125746OA-I00 HACIA UNA TERAPIA DIRIGIDA CONTRA EL CANCER: UTILIZACION DE... 157K€ Cerrado

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 168K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Cisplatin is a platinum-based complex used widely as a chemotherapeutic drug. However, due to its limitations, including narrow activity range and severe side effects, other transition metal complexes are investigated as antitumorur agents. Titanium complexes that previously reached clinical trials showed fair activity, and were mainly limited by rapid decomposition in water, within minutes. Titanium complexes of diamino bis(phenolato) (""salan"") ligands studied in our laboratory under the ERC grant demonstrate extremely high stability for up to weeks in water solutions. Importantly, they have shown great potency as anti-tumour agents towards a number of cells in vitro. Their activity exceeds that of cisplatin by up to two orders of magnitude. In particular, halogenated compounds at specific positions demonstrate a combination of exceptional hydrolytic stability and particularly high cytotoxicity, and are covered in a patent application. In addition, minor effect on regular cells was observed. As the titanium has been previously shown based on in vivo testing to be significantly less toxic than platinum, (and is commonly found in food and cosmetics), several pharmaceutical companies expressed interest in our compounds. However, in vivo activity and some mechanistic insights (required for FDA approval) are fundamental for allowing commercialization. Therefore, we propose to conduct a series of experiments that will bring this research to a more ""mature"" level suitable to be undertaken by pharmaceutical companies. These include in vivo testing on mice to establish safety and activity towards different cells and by different administration techniques, including IV. Additionally, as solubility is an issue, different formulations will be assessed. Basic mechanistic studies will include evaluating potential interaction with DNA. All these studies are not covered by the ERC grant, and will be conducted in collaboration with a biologist expert in cancer research."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores